-
Mashup Score: 0VJOncology – The video journal of oncology - 9 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Traditional tumor response assessments rely on radiographic scans after two months, often exposing patients to unnecessary toxicity before determining efficacy. Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, offers circulating tumor DNA (ctDNA) testing as a faster alternative, allowing response evaluation within around 3 weeks. By measuring baseline ctDNA levels and tracking changes over time, clinicians can quickly identify whether treatment is effective. Using a test which provides quantifiable ctDNA levels, a strong correlation between early ctDNA decline and radiographic response was reported. While further validation is needed, this approach could spare patients from ineffective treatments and enable faster therapy adjustment to improve outcomes. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around th
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥Dr Sakti Chakrabarti (@doctorC369) highlights ctDNA testing as a faster alternative to scans for assessing tumor response, enabling treatment evaluation in ~3 weeks and potentially improving outcomes: ➡️https://t.co/Pya95avWVp⬅️ @ASCO #GI25 #Oncology
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 9 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 10 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 10 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0
Aasma Shaukat, MD, MPH, NYU Grossman School of Medicine, New York, NY, comments on the potential of blood-based tests for colorectal cancer screening, highlighting their potential to increase screening rates and provide primary care providers with another option. Dr Shaukat emphasizes the importance of ensuring universal access to these tests, regardless of socioeconomic status, and making them available at various locations for convenient blood draws. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@AasmaShaukatMD of @nyugrossman highlights the potential of blood-based tests to boost colorectal cancer screening rates and improve access across all socioeconomic groups: ➡️https://t.co/PAC6ZBlrXG⬅️ @acso #GI25 #CRCSM
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 11 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2
-
-
Mashup Score: 0
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, highlights the importance of biomarkers in selecting patients for dual trastuzumab and pembrolizumab therapy in gastric cancer or gastroesophageal junction (G/GEJ) cancer. Targeted patient selection could enable de-escalation of chemotherapy, minimizing side effects while maintaining efficacy. With the rapidly evolving first-line treatment landscape, agents like claudin 18.2 and FGFR monoclonal antibodies are emerging. interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🚨 Esophageal Cancer Awareness Month 🚨 Optimising patient selection is key to improving outcomes in gastroesophageal junction cancer. Discover the latest insights on targeted therapies Watch now 👉 https://t.co/F3aodxsjA8 #EsophagealCancerAwareness #TargetedTherapies #GIsm
-
-
Mashup Score: 1Post-osimertinib landscape for NSCLC - 11 day(s) ago
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the complexity of the post-osimertinib space in non-small cell lung cancer (NSCLC), noting the resurgence of other drugs and the development of new targeted therapies, including antibody-drug conjugates (ADCs) such as patritumab deruxtecan and bispecific antibodies, as well as ongoing studies targeting C797S resistance. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥@AlexSpiraMDPhD of @VCSpecialists discusses evolving treatments in post-osimertinib #NSCLC, including ADCs, bispecifics, and strategies targeting C797S resistance: ➡️https://t.co/biE4dz71Mz⬅️ #LungCancer #ImmunoOnc #LCSM
-
-
Mashup Score: 0Optimizing the balance between efficacy & safety when administering T-DXd in gastric cancer - 12 day(s) ago
Hisato Kawakami, MD, PhD, Tohoku University, Sendai, Japan, discusses balancing efficacy and safety with the use of trastuzumab deruxtecan in patients with HER2+ gastric cancer, highlighting its high response rate and prolonged patient survival, but also emphasizing the need for caution in patients with a history of lung disease. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Oncologists1Tweet-
🎥Hisato Kawakami, MD, PhD, of @TohokuUniPR highlights the efficacy of trastuzumab deruxtecan in HER2+ gastric cancer while emphasizing caution in patients with prior lung disease due to ILD risk: ➡️https://t.co/REAmLtzfPQ⬅️ @asco #GI25 #ImmunoOnc #STCsm
-
📢1 week until all things GI cancer are debated virtually at #GDUGI2023! Keep an eye on https://t.co/ys1d8pDAKO for all the updates…💻 @GreatDebatesCME #GDUGI2023 #CRCSM #PancSM #ESOCSM #STCSM #HPBCSM https://t.co/Bj1V9ui2l2